[{"AccountsPayableCurrent_0_Q2_USD":145100000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_1_Q2_USD":113300000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_2_Q2_USD":220600000.0,"NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_1_Q2_USD":139300000.0,"NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_2_Q2_USD":269700000.0,"NumberOfOperatingSegments_2_Q2_segment":2.0,"NumberOfStatesInWhichEntityOperates_0_Q2_state":42.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":42000000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":212900000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":244900000.0,"OtherAssetsCurrent_0_Q2_USD":93600000.0,"OtherAssetsNoncurrent_0_Q2_USD":269700000.0,"OtherCostAndExpenseOperating_1_Q2_USD":172700000.0,"OtherCostAndExpenseOperating_2_Q2_USD":335000000.0,"OtherLiabilitiesCurrent_0_Q2_USD":550600000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":219100000.0,"NetIncomeLossAttributableToRedeemableNoncontrollingInterest_2_Q2_USD":5100000.0,"NetIncomeLossAttributableToRedeemableNoncontrollingInterest_1_Q2_USD":2700000.0,"NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_2_Q2_USD":49100000.0,"NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_1_Q2_USD":26000000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":6612900000.0,"LiabilitiesCurrent_0_Q2_USD":804500000.0,"LitigationSettlementExpense_1_Q2_USD":0.0,"LitigationSettlementExpense_2_Q2_USD":0.0,"LongTermDebtAndCapitalLeaseObligations_0_Q2_USD":3105700000.0,"LongTermDebtAndCapitalLeaseObligationsCurrent_0_Q2_USD":66800000.0,"MinorityInterest_0_Q2_USD":414100000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-4000000.0,"MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1_Q2_USD":23000000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-263900000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-321600000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":414400000.0,"NetIncomeLoss_1_Q2_USD":113300000.0,"NetIncomeLoss_2_Q2_USD":220600000.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q2_USD":28700000.0,"NetIncomeLossAttributableToNoncontrollingInterest_2_Q2_USD":54200000.0,"MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2_Q2_USD":45400000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":4600000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":6000000.0,"PartnersCapitalAccountContributions_2_Q2_USD":41800000.0,"RestrictedCashCurrent_0_Q2_USD":65000000.0,"RestrictedCashNoncurrent_0_Q2_USD":1600000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":1287700000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":2518100000.0,"RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_2_Q2_USD":46600000.0,"ShareBasedCompensation_2_Q2_USD":14800000.0,"StockholdersEquity_0_Q2_USD":1762000000.0,"RepaymentsOfSeniorDebt_2_Q2_USD":207300000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q2_USD":2176100000.0,"StockholdersEquityOther_1_Q2_USD":2300000.0,"SuppliesExpense_1_Q2_USD":50000000.0,"SuppliesExpense_2_Q2_USD":101900000.0,"UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1_Q2_USD":500000.0,"UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_2_Q2_USD":1000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":100200000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":100200000.0,"StockholdersEquityOther_2_Q2_USD":2500000.0,"Liabilities_0_Q2_USD":4403900000.0,"RepaymentsOfLongTermLinesOfCredit_2_Q2_USD":0.0,"PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0_Q2_USD":2391200000.0,"PartnersCapitalAccountContributions_1_Q2_USD":36000000.0,"PaymentsForProceedsFromOtherInvestingActivities_2_Q2_USD":1200000.0,"PaymentsForRepurchaseOfCommonStock_2_Q2_USD":0.0,"PaymentsForSoftware_2_Q2_USD":10000000.0,"PaymentsOfDistributionsToAffiliates_2_Q2_USD":0.0,"PaymentsOfDividendsCommonStock_2_Q2_USD":56900000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":16400000.0,"RedeemableNoncontrollingInterestEquityCarryingAmount_0_Q2_USD":32900000.0,"PaymentsToAcquireBusinessesNetOfCashAcquired_2_Q2_USD":97700000.0,"PaymentsToMinorityShareholders_2_Q2_USD":52700000.0,"ProceedsFromContributionsFromAffiliates_2_Q2_USD":36100000.0,"ProceedsFromIssuanceOfSeniorLongTermDebt_2_Q2_USD":0.0,"ProceedsFromLongTermLinesOfCredit_2_Q2_USD":45000000.0,"ProceedsFromPaymentsForOtherFinancingActivities_2_Q2_USD":100000.0,"ProfitLoss_1_Q2_USD":142000000.0,"ProfitLoss_2_Q2_USD":274800000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":212700000.0,"LaborAndRelatedExpense_2_Q2_USD":1395400000.0,"LaborAndRelatedExpense_1_Q2_USD":708200000.0,"InterestExpense_2_Q2_USD":84600000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":220600000.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q2_USD":28700000.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2_Q2_USD":54200000.0,"CostsAndExpenses_1_Q2_USD":1068700000.0,"CostsAndExpenses_2_Q2_USD":2091400000.0,"DebtAndCapitalLeaseObligations_0_Q2_USD":3172500000.0,"DeferredIncomeTaxExpenseBenefit_2_Q2_USD":6200000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":113300000.0,"DeferredIncomeTaxLiabilitiesNet_0_Q2_USD":61700000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":125900000.0,"DividendsCommonStockCash_1_Q2_USD":28100000.0,"DividendsCommonStockCash_2_Q2_USD":55900000.0,"EarningsPerShareBasic_1_Q2_USD":1.14,"EarningsPerShareBasic_2_Q2_USD":2.22,"EarningsPerShareDiluted_2_Q2_USD":2.2,"EarningsPerShareDiluted_1_Q2_USD":1.13,"DepreciationDepletionAndAmortization_1_Q2_USD":63400000.0,"FinanceLeaseLiability_0_Q2_USD":422900000.0,"CommonStockDividendsPerShareDeclared_2_Q2_USD":0.56,"CommitmentsAndContingencies_0_Q2_USD":null,"AccountsReceivableNetCurrent_0_Q2_USD":627500000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q2_USD":800000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":16400000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":12000000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":14800000.0,"AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2_Q2_USD":139300000.0,"Assets_0_Q2_USD":6612900000.0,"CommonStockDividendsPerShareDeclared_1_Q2_USD":0.28,"AssetsCurrent_0_Q2_USD":859300000.0,"BusinessAcquisitionsProFormaNetIncomeLoss_2_Q2_USD":221900000.0,"BusinessAcquisitionsProFormaRevenue_1_Q2_USD":1295000000.0,"BusinessAcquisitionsProFormaRevenue_2_Q2_USD":2537200000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":73200000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":139800000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-171100000.0,"CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2_Q2_USD":-600000.0,"BusinessAcquisitionsProFormaNetIncomeLoss_1_Q2_USD":113800000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":99000000.0,"FinanceLeasePrincipalPayments_2_Q2_USD":11800000.0,"GainsLossesOnExtinguishmentOfDebt_2_Q2_USD":-1000000.0,"IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_2_Q2_USD":0.0,"IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_2_Q2_USD":0.0,"IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1_Q2_USD":0.0,"IncomeLossFromEquityMethodInvestments_1_Q2_USD":1000000.0,"IncomeLossFromEquityMethodInvestments_2_Q2_USD":2000000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":39500000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":74000000.0,"IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_1_Q2_USD":0.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":6600000.0,"IncreaseDecreaseInAccruedSalaries_2_Q2_USD":27400000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":17200000.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":10300000.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1_Q2_shares":1200000.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2_Q2_shares":1200000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":435500000.0,"InterestExpense_1_Q2_USD":41800000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":38100000.0,"GainsLossesOnExtinguishmentOfDebt_1_Q2_USD":-1000000.0,"IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1_Q2_USD":-300000.0,"IncomeLossFromDiscontinuedOperationsNetOfTax_2_Q2_USD":-300000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":54200000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":92800000.0,"Goodwill_0_Q2_USD":2412300000.0,"IncomeLossFromContinuingOperations_1_Q2_USD":113600000.0,"IncomeLossFromContinuingOperations_2_Q2_USD":220900000.0,"IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_1_Q2_USD":28700000.0,"IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_2_Q2_USD":54200000.0,"IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2_Q2_USD":-300000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":349100000.0,"IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1_Q2_USD":142300000.0,"IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2_Q2_USD":275100000.0,"IncomeLossFromContinuingOperationsPerBasicShare_1_Q2_USD":1.14,"IncomeLossFromContinuingOperationsPerBasicShare_2_Q2_USD":2.22,"IncomeLossFromContinuingOperationsPerDilutedShare_1_Q2_USD":1.13,"IncomeLossFromContinuingOperationsPerDilutedShare_2_Q2_USD":2.2,"IncomeLossFromDiscontinuedOperationsNetOfTax_1_Q2_USD":-300000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":181800000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":99000000.0,"Ticker":"EHC","CIK":"785161","name":"ENCOMPASS HEALTH CORP","OfficialName":"Encompass Health Corporation Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"7151596423.0","Country":"United States","Sector":"Health Care","Industry":"Medical Specialities","Market":"NYSE","SP500":"nan","filed":"20210803"}]